What is Hereditary Cancer and GenoXhere?

What is Hereditary Cancer and GenoXhere?

Approximately 5-10% of all cancers arise on a hereditary background — pathogenic germline variants in cancer-predisposing genes that are inherited from a parent. Hallmark features of hereditary cancer include young age of onset, multiple primary cancers in the same individual, multiple affected family members across generations, and rare/specific cancer types (e.g. male breast cancer, medullary thyroid cancer, retinoblastoma). Identification of hereditary cancer enables targeted surveillance, risk-reducing surgery, chemoprevention, and access to molecularly targeted therapy (e.g. PARP inhibitors for BRCA-related cancers).

The GenoXhere oncology panel provides comprehensive germline analysis of high- and moderate-penetrance cancer-predisposing genes including BRCA1, BRCA2, PALB2, ATM, CHEK2, TP53, PTEN, CDH1, STK11, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, VHL, RET, MEN1, and others. The panel is offered in two configurations: Prime 160 genes for general hereditary cancer assessment and Plus 360 genes for extended hematologic and rare-cancer coverage. Sample: 2-4 mL EDTA peripheral blood. Reporting time: 8 weeks (±2). Results are interpreted by ACMG/AMP 2015 variant classification, and post-test genetic counseling is mandatory.

Herediter Kanser Nedir?

Herediter kanser, bir kişinin genetik materyalindeki belirli bir mutasyon nedeniyle kansere yakalanma riskinin arttığı bir tür kanserdir. Bu mutasyonlar, bir kişinin doğumundan itibaren var olan genetik değişikliklerdir ve bu değişiklikler kanser hücrelerinin gelişmesine ve büyümesine neden olabilir. GenoXhere ise heretider kanserlere karşı Genoks Genetik Hastalıklar Değerlendirme Merkezi’nin onkoloji panelidir.

Herediter kanser, özellikle ailede birden fazla kanser vakasının görüldüğü durumlarda düşünülmelidir. Örneğin, meme kanseri, over kanseri, kolon kanseri, pankreas kanseri ve bazı lösemi türleri gibi bazı kanserler, herediter kanser sendromlarına neden olabilir.

Herediter kanser sendromları, özellikle kanser gelişimi açısından yüksek risk taşıyan kişiler için düzenli taramalar ve erken teşhisin sağlanmasına yardımcı olacak genetik testler yoluyla tanımlanabilir. Bu kişiler, kanser gelişimi açısından risk altında oldukları için, sağlıklı yaşam tarzı değişiklikleri, düzenli taramalar ve gerekirse tedavi seçenekleri gibi önlemler alarak kanser risklerini azaltabilirler.

GenoXhere Nedir?
GenoXhere; heretider kanserlere karşı Genoks Genetik Hastalıklar Değerlendirme Merkezi’nin onkoloji panelidir. GenoXhere, GenoXhere Prostat, Genoks Meme / Over, GenoXhere Kolon 23 Gen ve GenoXhere BRCA panellerinin yanı sıra Prime 160 Gen ve Plus 360 Gen olmak üzere iki farklı paket ile sunulmaktadır.

GenoXhere Prime 160 Gen

Gen :	ABCB11 \| AIP \| ALK \| ANKRD26 \| APC \| ATM \| ATR \| AXIN2 \| BAP1 \| BARD1 \| BLM \| BMPR1A \| BRAF \| BRCA1, BRCA2 \| BRIP1 \| CASR \| CBL \| CDC73 \| CDH1 \| CDK4 \| CDKN1B \| CDKN1C \| CDKN2A \| CEBPA \| CEBPE \| CEP57 \| CFTR \| CHEK2 \| COL7A1 \| CTC1 \| CTRC \| CYLD \| DDB2 \| DICER1 \| DIS3L2 \| DKC1 \| DOCK8 \| EGFR \| EGLN1 \| ELANE \| EPCAM \| ERCC1 \| ERCC2 \| ERCC3 \| ERCC4 \| ERCC5 \| EXO1 \| EXT1 \| EXT2 \| EZH2 \| FAH \| FANCA \| FANCB \| FANCC \| FANCD2 \| FANCE \| FANCF \| FANCG \| FANCI \| FANCL \| FANCM \| FH \| FLCN \| G6PC3 \| GALNT12 \| GATA2 \| GBA \| GJB2 \| GPC3 \| GREM1 \| HAX1 \| HFE \| HMBS \| HNF1A \| HOXB13 \| HRAS \| ITK \| KIF1B \| KIT \| KITLG \| KRAS\| MAP2K1 \| MAP2K2 \| MAX \| MC1R \| MEN1 \| MET \| MITF \| MLH1 \| MLH3 \| MPL \| MRE11 \| MRE11A \| MSH2 \| MSH3 \| MSH6 \| MTAP \| MUTYH \| NBN \| NF1 \| NF2 \| NHP2 \| NOP10 \| NPAT \| NRAS \| NSD1 \| NSUN2 \| NTHL1 \| PALB2\| PALLD \| PAX5 \| PDGFRA \| PHOX2B \| PMS1 \| PMS2 \| POLD1 \| POLH \| PPM1D \| PRF1 \| PRKAR1A \| PRSS1 \| PTCH1 \| PTCH2 \| PTEN \| PTPN11 \| RAD50 \| RAD51C \| RAD51D \| RAF1 \| RB1 \| RECQL4 \| RET \| RHBDF2 \| RMRP \| RUNX1 \| SAMD9 \| SBDS \| SDHA \| SDHAF2 \| SDHB \| SDHC \| SDHD \| SERPINA1 \| SH2D1A \| SHOC2 \| SLC25A13 \| SLC45A2 \| SLX4 \| SMAD4 \| SMARCA4 \| SMARCB1 \| SMARCE1 \| SOS1 \| SPINK1 \| SPRED1 \| SRP72 \| STK11 \| SUFU \| TERC \| TERT\| TINF2 \| TMEM127 \| TP53 \| TSC1 \| TSC2 \| TYR \| VHL \| WRAP53 \| WRN \| WT1 \| XPA \| XPC \| XRCC2 \| XRCC2
Yöntem :	NGS
Raporlama Süresi :	8 Hafta (+/- 2 Hafta)
Prenatal/ Postnatal:	Postnatal
Gerekli Numune:	EDTA’lı Kan (2-4 ml)
Saklamama / Taşıma Sıcaklığı:	+ 4C°/ + 24C°

GenoXhere Plus 360 Gen

Gen :	ABCA3 \| ABCB7 \| ABCG5 \| ABCG8 \| ACD \| ACTB \| ACTN1 \| ADAMTS13 \| AIP \| AK1 \| AK2 \| ALAS2 \| ALK \| AMN \| ANK1 \| ANKRD26 \| AP3B1 \| AP3D1 \| APC \| ARPC1B \| ATM \| ATR \| ATRX \| AXIN2 \| BAP1 \| BARD1 \| BLM \| BLOC1S3 \| BLOC1S6 \| BMPR1A \| BRAF \| BRCA1 \| BRCA2 \| BRIP1 \| BUB1B \| C15ORF41 \| C6ORF25 \| CBL \| CD59 \| CD70 \| CDAN1 \| CDC42 \| CDC73 \| CDH1 \| CDK4 \| CDKN1B \| CDKN1C \| CDKN2A \| CEBPA \| CECR1 \| CEP57 \| CHEK2\| CLCN7 \| CLPB \| CSF2RA \| CSF3R \| CTC1 \| CTLA4 \| CTNNA1 \| CTSC \| CUBN \| CXCR4 \| CYB5R3 \| CYCS \| CYLD \| DDB2 \| DDX41 \| DHFR \| DICER1 \| DIS3L2 \| DKC1 \| DNAJC21 \| DNASE2 \| DTNBP1 \| EFL1 \| EGFR \| EGLN1 \| ELANE \| EPAS1 \| EPB41 \| EPB42 \| EPCAM \| EPOR \| ERCC1 \| ERCC2 \| ERCC3 \| ERCC4 \| ERCC5 \| ERCC6L2 \| ETV6 \| EXO1 \| EXT1 \| EXT2 \| EZH2 \| F10 \| F11 \| F12 \| F13A1 \| F13B \| F2 \| F5 \| F7 \| F8 \| F9 \| FADD \| FAM111B \| FANCA \| FANCB \| FANCC \| FANCD2 \| FANCE \| FANCF \| FANCG \| FANCI \| FANCL \| FANCM \| FAS \| FASLG \| FGA \| FGB \| FGG \| FH \| FLCN \| FLI1 \| FLNA \| FYB \| G6PC3 \| G6PD \| GALNT12 \| GATA1 \| GATA2 \| GBA \| GCLC \| GFI1 \| GFI1B \| GGCX \| GINS1 \| GLRX5 \| GP1BA \| GP9 \| GPC3 \| GPI \| GPR101 \| GPR143 \| GREM1 \| GSS \| HAVCR2 \| HAX1 \| HBA1 \| HBA2 \| HBB \| HFE \| HK1 \| HMOX1 \| HNF1A \| HOXA11 \| HOXB13 \| HPS1 \| HPS3 \| HPS4 \| HPS5 \| HPS6 \| HRAS \| IFNGR2 \| IKZF1 \| ITGA2 \| ITGA2B \| ITGB3 \| ITK \| JAGN1 \| JAK2 \| KCNN4 \| KIF1B \| KIF23 \| KIT \| KITLG \| KLF1 \| KRAS \| LAMTOR2 \| LMAN1 \| LPIN2 \| LYST \| LZTR1 \| MAGT1 \| MAP2K1 \| MAP2K2 \| MASTL \| MAX \| MCFD2 \| MECOM \| MEN1 \| MET \| MITF \| MKL1 \| MLH1 \| MLH3 \| MPL \| MRE11A \| MSH2 \| MSH3 \| MSH6 \| MTHFD1 \| MTR \| MUTYH \| MYH9 \| MYO5A \| NAF1 \| NBEAL2 \| NBN \| NF1 \| NF2 \| NHP2 \| NOP10 \| NRAS \| NSD1 \| NSUN2 \| NT5C3A \| NTHL1 \| OBFC1 \| 37257 \| P2RY12 \| PALB2 \| PARN \| PAX5 \| PC \| PDGFRA \| PDHA1 \| PDHX \| PGK1 \| PGM3 \| PHOX2B \| PIEZO1 \| PKLR \| PMS1 \| PMS2 \| POLD1 \| POLE \| POLH \| POT1 \| PPM1D \| PRF1 \| PRKACG \| PRKAR1A \| PROC \| PROS1 \| PTCH1 \| PTEN \| PTPN11 \| PUS1 \| RAB27A \| RAC2 \| RAD50 \| RAD51C \| RAD51D \| RAF1 \| RASA2 \| RASGRP2 \| RB1 \| RBM8A \| RECQL \| RECQL4 \| REN \| REST \| RET \| RHAG \| RHBDF2 \| RIT1 \| RNF168 \| RPL11 \| RPL15 \| RPL26 \| RPL27 \| RPL31 \| RPL35A \| RPL5 \| RPS10 \| RPS19 \| RPS20 \| RPS24 \| RPS26 \| RPS28 \| RPS29 \| RPS7 \| RRAS \| RTEL1 \| RUNX1 \| SAMD9 \| SAMD9L \| SBDS \| SDHA \| SDHAF2 \| SDHB \| SDHC \| SDHD \| SEC23B \| SERPINC1 \| SERPINF2 \| SFTPB \| SFTPC \| SH2D1A \| SHOC2 \| SLC11A2 \| SLC19A2 \| SLC25A38 \| SLC37A4 \| SLC45A2 \| SLC46A1 \| SLC4A1 \| SLFN14 \| SLX4 \| SMAD4 \| SMARCA4 \| SMARCB1 \| SMARCD2 \| SMARCE1 \| SOS1 \| SOS2 \| SPRED1 \| SPTA1 \| SPTB \| SRC \| SRP54 \| SRP72 \| STAT3 \| STK11 \| STX11 \| STXBP2 \| SUFU \| TBXA2R \| TBXAS1 \| TCN2 \| TERC \| TERT \| TF \| THBD \| THPO \| TINF2 \| TMEM127 \| TMPRSS6 \| TP53 \| TPI1 \| TRIP13 \| TRNT1 \| TSC1 \| TSC2 \| TUBB1 \| TYR \| TYRP1 \| UBE2T \| UNC13D \| USB1 \| VHL \| VKORC1 \| VPS13B \| VPS45 \| VWF \| WAS \| WDR1 \| WIPF1 \| WRAP53 \| WRN
Yöntem :	NGS
Raporlama Süresi :	8 Hafta (+/- 2 Hafta)
Prenatal/ Postnatal:	Postnatal
Gerekli Numune:	EDTA’lı Kan (2-4 ml)
Saklamama / Taşıma Sıcaklığı:	+ 4C°/ + 24C°

Detaylı Bilgi Almak İçin Bize Mesaj Atabilirsiniz.

[contact-form-7 id=”710″ title=”genetik başvuru”]

Genoks Genetik Hastalıklar Değerlendirme Merkezi T.C. Sağlık Bankanlığınca denetlenen ve GHDM-SM/06.15/01 ruhsat numarası ile hizmet veren sağlık kuruluşudur. genoks.com.tr web sayfasında bulunan bilgiler, genetik değerlendirme ve/veya tanı-teşhis amaçlı kullanılmamalıdır. Tüm içerikler bilgilendirme amaçlıdır.

Leave a Reply